LivingGLP1
Study S001436

Cardiovascular Effects of GLP-1 Receptor Activation

Included trial: extracted dataClinicalTrials.gov recordStudy Protocol and Statistical Analysis Plan (PDF)

Registration

Registration
NCT03101930
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE4
Masking
QUADRUPLE
Status
COMPLETED
Enrollment
329
Start
2017-05-01
Primary completion
2021-06-24
Lead sponsor
Vanderbilt University Medical Center
Conditions
Obesity; PreDiabetes
Interventions
DRUG:Liraglutide; DRUG:Sitagliptin; OTHER:hypocaloric diet; DRUG:Placebos; DRUG:Exendin (9-39)
Results posted
TRUE
Individual participant data sharing
YES

Registered primary outcomes

  • Change in Flow-mediated Dilation [Baseline to 2 and 14 weeks]
  • Urine Albumin-to-creatinine Ratio [Baseline to 13 weeks]
  • Change in Plasminogen Activator Inhibitor-1 [Baseline to 2 and 14 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0013597Comparative Effects of Weight Loss and Incretin-Based Therapies on Vascular Endothelial Function, Fibrinolysis, and Inflammation: A Randomized, Controlled Trial
Mashayekhi M, medRxiv
2022Randomized trialDOIcites ClinicalTrials.gov:NCT03101930